Stereotaxis (STXS) Total Non-Current Liabilities (2010 - 2026)
Stereotaxis (STXS) posted quarterly Total Non-Current Liabilities of $29.3 million for Q1 2026, down 6.23% year-over-year from $31.3 million in Q1 2025, and up 1.8% quarter-over-quarter from $28.8 million in Q4 2025.
Stereotaxis (STXS) Total Non-Current Liabilities (2010 - 2026) Analysis & Trends
Stereotaxis (STXS) has reported Total Non-Current Liabilities for 17 consecutive years, with $29.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Non-Current Liabilities fell 6.23% year-over-year to $29.3 million; the TTM figure through Mar 2026 stood at $29.3 million (down 6.23% YoY), while the FY2025 annual figure was $28.8 million, down 1.23% from the prior year.
- Total Non-Current Liabilities climbed to $29.3 million in Q1 2026 per STXS's latest filing, from $28.8 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $34.7 million in Q3 2024 and bottomed at $19.2 million in Q2 2024.
- Historically, Total Non-Current Liabilities has averaged $25.0 million across 5 years, with a median of $21.4 million in 2022.
- Annual changes were most pronounced in 2023 — Total Non-Current Liabilities retreated 10.5% — and 2025, when it jumped 73.53%.
- Stereotaxis' Total Non-Current Liabilities stood at $21.4 million in 2022, then retreated by 6.94% to $19.9 million in 2023, then soared by 46.22% to $29.2 million in 2024, then fell by 1.23% to $28.8 million in 2025, then increased by 1.8% to $29.3 million in 2026.
- Business Quant data shows STXS's Total Non-Current Liabilities at $29.3 million in Q1 2026, $28.8 million in Q4 2025, and $33.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 134.13 Bn | 128.91 Bn | 1.96 Bn | 1.92 Bn |
| 2 | Becton Dickinson | 52.76 Bn | 51.90 Bn | 2.32 Bn | 48.34 Bn |
| 3 | Alcon | 35.81 Bn | 34.46 Bn | 1.68 Bn | 6.34 Bn |
| 4 | Resmed | 33.72 Bn | 32.25 Bn | 861.22 Mn | 985.45 Mn |
| 5 | Medline | 29.38 Bn | 26.70 Bn | 2.22 Bn | 17.56 Bn |
| 6 | West Pharmaceutical Services | 25.00 Bn | 24.57 Bn | 329.20 Mn | 996.30 Mn |
| 7 | Solventum | 15.46 Bn | 15.06 Bn | 1.29 Bn | 8.96 Bn |
| 8 | Cooper Companies | 14.88 Bn | 14.74 Bn | 735.40 Mn | 3.98 Bn |
| 9 | Baxter International | 13.58 Bn | 11.43 Bn | 1.03 Bn | 12.41 Bn |
| 10 | Stereotaxis | 141.91 Mn | 127.29 Mn | 3.79 Mn | 29.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 29.32 Mn |
| Dec 31, 2025 | 28.81 Mn |
| Sep 30, 2025 | 32.95 Mn |
| Jun 30, 2025 | 33.31 Mn |
| Mar 31, 2025 | 31.27 Mn |
| Dec 31, 2024 | 29.17 Mn |
| Sep 30, 2024 | 34.66 Mn |
| Jun 30, 2024 | 19.20 Mn |
| Mar 31, 2024 | 19.38 Mn |
| Dec 31, 2023 | 19.95 Mn |
| Sep 30, 2023 | 20.19 Mn |
| Jun 30, 2023 | 21.30 Mn |
| Mar 31, 2023 | 21.37 Mn |
| Dec 31, 2022 | 21.43 Mn |
| Sep 30, 2022 | 22.56 Mn |
| Jun 30, 2022 | 20.95 Mn |
| Mar 31, 2022 | 19.32 Mn |
| Dec 31, 2021 | 21.34 Mn |
| Sep 30, 2021 | 21.55 Mn |
| Jun 30, 2021 | 15.08 Mn |